Toxicidad por inmunoterapia en cáncer: una visión oncológica para el internista
DOI:
https://doi.org/10.18041/2665-427X/ijeph.2.9900Palabras clave:
inmunoterapia, tratamiento del cancer, puntos de control del sistema inmune., eventos adversos de inmunoterapia., Efectos adversos, toxicidad, quimioterapia, cáncer, antígeno 4 de Linfocitos-T citotóxicos, anticuerpos anti-PD1, anticuerpos anti-PDL1, hepatotoxicidad, hepatitis, meningitis, tiroiditisResumen
La inmunoterapia es considerada uno de los avances más recientes en el tratamiento del cáncer. Gracias a los avances tecnológicos desarrollados en las últimas tres décadas en inmunología y oncología, hemos visto un prometedor auge en el tratamiento de diferentes patologías oncológicas mediante el uso del sistema inmunológico del paciente, especialmente con el desarrollo de anticuerpos dirigidos contra varios puntos de control del sistema inmunitario (Immune Checkpoint Blockade). Se hará una breve revisión del mecanismo fisiopatológico de las irEA más frecuentes reportadas en la literatura, así como su incidencia y prevalencia según los diferentes fármacos de inmunoterapia disponibles para el tratamiento de las diferentes neoplasias sólidas y hematológicas
Descargas
Referencias
Dobosz P, Dzieciatkowski T. The intriguing history of cancer immunotherapy. Front Immunol. 2019; 10: 2965. doi: 10.3389/fimmu.2019.02965
Esfahani K, Meti N, Miller WH Jr, Hudson M. Adverse events associated with immune checkpoint inhibitor treatment for cancer. CMAJ. 2019; 191(2): E40-E46. Doi: 10.1503/cmaj.180870.
Emens LA, Ascierto PA, Darcy PK, Demaria S, Eggermont AMM, Redmond WL, et al. Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape. Eur J Cancer. 2017; 81: 116-129. doi: 10.1016/j.ejca.2017.01.035.
Akinleye A, Rasool Z. Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. J Hematol Oncol. 2019;12(1):92. doi: 10.1186/s13045-019-0779-5.
Krummel MF, Allison JP. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med 1996; 183: 2533-40. doi: 10.1084/jem.183.6.2533
Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002; 8: 793-800. doi: 10.1038/nm730.
Boussiotis VA. Molecular and biochemical aspects of the PD-1 checkpoint pathway. N Engl J Med 2016; 375: 1767-78. doi: 10.1056/NEJMra1514296.
Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 1995; 3: 541-7. doi: 10.1016/1074-7613(95)90125-6.
Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science. 1995; 270: 985-8. doi: 10.1126/science.270.5238.985.
Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019; 16: 563-580. doi: 10.1038/s41571-019-0218-0.
Eggermont, AMM, Chiarion-Sileni V, Grob J-J, Dummer R, Wolchok JD, Schmidt H, et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med. 2016; 375: 1845-1855. doi: 10.1056/NEJMoa1611299.
Hodi FS, O´Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363: 711-723. doi: 10.1056/NEJMoa1003466.
Cuzzubbo S, Javeri F, Tissier M, Roumi A, Barlog C, Doridam J, et al. Neurological adverse events associated with immune checkpoint inhibitors: review of the literature. Eur J Cancer. 2017; 73: 1-8. doi: 10.1016/j.ejca.2016.12.001.
Lee JB, Kim HR, Ha S-J. Immune Checkpoint Inhibitors in 10 Years: Contribution of Basic Research and Clinical Application in Cancer Immunotherapy. Immune Netw. 2022; 22(1): e2. doi: 10.4110/in.2022.22.e2.
Esfahani K, Meti N, Miller WH Jr, Hudson M. Adverse events associated with immune checkpoint inhibitor treatment for cancer. CMAJ. 2019; 191(2):E40-E46. doi: 10.1503/cmaj.180870.
Teulings H-E, Limpens J, Jansen SN, Zwinderman AH, Reitsma JB, Spuls PI, et al. Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. J Clin Oncol. 2015; 33(7): 773-81. doi: 10.1200/JCO.2014.57.4756.
Min LCK, Li S, Tran DC, Zhu GA, Kim J, Kwong BY, Chang ALS. Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: A retrospective case-control study. J Am Acad Dermatol. 2018; 79(6): 1047-1052. doi: 10.1016/j.jaad.2018.05.035.
Belum VR, Benhuri B, Postow MA, Hellmann MD, Lesokhin AM, Segal NH, et al Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer. 2016; 60: 12-25. doi: 10.1016/j.ejca.2016.02.010.
Dougan M. Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract. Front Immunol. 2017; 8: 1547. doi: 10.3389/fimmu.2017.01547.
Abu-Sbeih H, Ali FS, Luo W, Qiao W, Raju GS, Wang Y. Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis. J Immunother Cancer. 2018; 6(1): 95. doi: 10.1186/s40425-018-0411-1.
Johnson DH, Zobniw CM, Trinh VA, Ma J, Bassett RL, Abdel-Wahab N, et al. Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. J Immunother Cancer. 2018; 6(1): 103. doi: 10.1186/s40425-018-0412-0.
Kanai, T. et al. Blockade of B7-H1 suppresses the development of chronic intestinal inflammation. J Immunol. 2003; 171: 4156-4163. doi: 10.4049/jimmunol.171.8.4156.
Reynoso ED, Elpek KG, Francisco L, Bronson R, Bellemare-Pelletier A, Sharpe AH, et al. Intestinal tolerance is converted to autoimmune enteritis upon PD-1 ligand blockade. J Immunol. 2009; 182: 2102-2112. doi: 10.4049/jimmunol.0802769.
Chuzi S, Tavora F, Cruz M , Costa R, Kwang CY, Carneiro BA, et al. Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitorrelated pneumonitis. Cancer Manag Res. 2017; 9: 207-213. doi: 10.2147/CMAR.S136818.
Nishino M, Giobbie-Hurder A, Hatabu H, Ramaiya NH, Hodi FS. Incidence of programmed cell death 1 inhibitor- related pneumonitis in patients with advanced cancer: a systematic review and meta- analysis. JAMA Oncol. 2016; 2: 1607-1616. doi: 10.1001/jamaoncol.2016.2453.
Naidoo J, Wang X, Woo KM, Lyriboz T , Halpenny D, Cunningham J, et al. Pneumonitis in patients treated with anti- programmed death-1/programmed death ligand 1 therapy. J Clin Oncol. 2017; 35: 709-717. doi: 10.1200/JCO.2016.68.2005.
Koelzer VH, Rothschild SI, Zihler D, Wicki A, Willi B, Willi N, et al. Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors- an autopsy study. J Immunother Cancer. 2016; 4: 13. doi: 10.1186/s40425-016-0117-1.
Faje A. Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights. Pituitary. 2016; 19: 82-92. doi: 10.1007/s11102-015-0671-4
Blansfield JA, Beck KE, Tran K, Yang JC, Hughes MS, Kammula US, et al. Cytotoxic T- lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother. 2005; 28: 593-598. doi: 10.1097/01.cji.0000178913.41256.06.
Corsello SM, Barnabei A, Marchetti P, De Vecchis L, Salvatori R, Torino F. Endocrine side effects induced by immune checkpoint inhibitors. J. Clin. Endocrinol. Metab. 2013; 98: 1361-1375. doi: 10.1210/jc.2012-4075.
Iwama S. De Remigis A, Callahan MK, Slovin SF, Wolchok JD, Caturegli P. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci Transl Med. 2014; 6: 230ra245. doi: 10.1126/scitranslmed.3008002.
Caturegli P, Di Dalmazi G, Lombardi M, Grosso F, Larman HB, Larman T, et al. Hypophysitis secondary to cytotoxic T- lymphocyte-associated protein 4 blockade: insights into athogenesis from an autopsy series. Am J Pathol. 2016; 186: 3225-3235. doi: 10.1016/j.ajpath.2016.08.020.
Gonzalez- Rodriguez E, Rodriguez-Abreu D; Spanish Group for Cancer Immuno-Biotherapy (GETICA). Immune checkpoint inhibitors: review and management of endocrine adverse events. Oncologist. 2016; 21: 804-816. doi: 10.1634/theoncologist.2015-0509.
Mahmood SS, Fradley MG, Cohen JV, Nohria A, Reynolds KL, Heinzerling LM, et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol. 2018; 71: 1755-1764. doi: 10.1016/j.jacc.2018.02.037.
Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016; 375: 1749-1755 (2016). doi: 10.1056/NEJMoa1609214.
Moslehi JJ, Salem JE, Sosman JA, Lebrun- Vignes B, Johnson DB. Increased reporting of fatal immune checkpoint inhibitor- associated myocarditis. Lancet. 2018; 391: 933. doi: 10.1016/S0140-6736(18)30533-6.
Heinzerling L, Ott PA, Hodi FS, Husain AN, Tajmir-Riahi A, Tawbi H, et al. Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer. 2016; 4: 50. doi: 10.1186/s40425-016-0152-y.
Varricchi G, Galdiero MR, Marone G, Criscuolo G, Triassi M, Bonaduce D, et al. Cardiotoxicity of immune checkpoint inhibitors. ESMO Open. 2017; 2: e000247. doi: 10.1136/esmoopen-2017-000247.
Kao JC, Liao B, Markovic SN, Klein CJ , Naddaf E, Staff NP, et al. Neurological complications associated with anti- programmed death 1 (PD-1) antibodies. JAMA Neurol. 2017; 74: 1216-1222. doi: 10.1001/jamaneurol.2017.1912.
Williams TJ, Benavides DR, Patrice K-A, Dalmau JO, Ribeiro deÁAL, Le DT, et al. Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer. JAMA Neurol. 2016; 73: 928-933. doi: 10.1001/jamaneurol.2016.1399.
Brown MP, Hissaria P, Hsieh AH, Kneebone C. Vallat W. Autoimmune limbic encephalitis with anticontactin-associated protein- like 2 antibody secondary to pembrolizumab therapy. J Neuroimmunol. 2017; 305: 16-18. doi: 10.1016/j.jneuroim.2016.12.016.
Papadopoulos KP, Romero RS, Gonzalez G, Dix JE, Lowy I, Fury M. Anti- Hu-associated autoimmune limbic encephalitis in a patient with PD-1 inhibitor- responsive myxoid chondrosarcoma. Oncologist. 2018; 23: 118-120. doi: 10.1634/theoncologist.2017-0344.
Makarious D, Horwood K, Coward JIG. Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors. Eur J Cancer. 2017; 82: 128-136. doi: 10.1016/j.ejca.2017.05.041.
Wang W, Lie P, Guo M, He J. Risk of hepatotoxicity in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta- analysis of published data. Int J Cancer. 2017; 141: 1018-1028. doi: 10.1002/ijc.30678.
Suzman DL, Pelosof L, Rosenberg A, Avigan MI. Hepatotoxicity of immune checkpoint inhibitors: an evolving picture of risk associated with a vital class of immunotherapy agents. Liver Int. 2018; 38: 976-987. doi: 10.1111/liv.13746.
Karamchandani DM, Chetty R. Immune checkpoint inhibitor- induced gastrointestinal and hepatic injury: pathologists' perspective. J Clin Pathol. 2018; 71: 665-671. doi: 10.1136/jclinpath-2018-205143
Johncilla M, Misdraji J, Pratt DS, Agoston AT, Lauwers GY, Srivastava A, et al. Ipilimumab- associated hepatitis: clinicopathologic characterization in a series of 11 cases. Am J Surg Pathol. 2015; 39: 1075-1084. doi: 10.1097/PAS.0000000000000453.
Butt S, Bhaumik S. Acute demyelinating polyneuropathy caused by nivolumab in a man with metastatic non- small cell lung cancer. J Gerontol Geriatr Res. 2016; 5: 302. Doi: 10.4172/2167-7182.1000302.
Descargas
Publicado
Versiones
- 2023-04-26 (2)
- 2022-12-30 (1)
Número
Sección
Licencia
Derechos de autor 2022 Interdisciplinary Journal of Epidemiology and Public Health
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
-
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
-
NonCommercial — You may not use the material for commercial purposes.
-
NoDerivatives — If you remix, transform, or build upon the material, you may not distribute the modified material.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
